Oncology | IND Enabling Drugs | KOREA, REPUBLIC OF

Bridge Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea

Lead Product(s): BBT-176,Anti-EGFR antibodies

Therapeutic Area: Oncology

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

Details:

On IND clearance in South Korea, Bridge Biotherapeutics plans to initiate a dose escalation study as the first part of the phase I/II study in Korea to find the maximum tolerable dose of BBT-176.

Genome & Company

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

First Anti-Cancer Microbiome Therapeutic Receives FDA IND Clearance in Asia

Lead Product(s): GEN-001,Avelumab

Therapeutic Area: Oncology

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2020

Details:

Genome & Company which sponsor clinical trial of combination therapy of anti-cancer microbiome and anti-PD1/anti-PD-L1 drug receives FDA IND clearance for GEN-001,

Bridge Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC

Lead Product(s): BBT-176,Anti-EGFR antibodies

Therapeutic Area: Oncology

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2020

Details:

Bridge Biotherapeutics will start a dose escalation study as the 1st part of phase I/II study in Korea to find the maximum tolerated dose and to observe safety, and anti-tumor efficacy of BBT-176.

Find

Find FDA Investigational New Drug (IND) Submissions for Oncology in KOREA, REPUBLIC OF

Korea Republic Of

A collaboration with SCORR Marketing

Product Type

Companies

Bridge Biotherapeutics

Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea

Genome & Company

First Anti-Cancer Microbiome Therapeutic Receives FDA IND Clearance in Asia

Bridge Biotherapeutics

Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC